Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2005

Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonistsfor postoperative nausea and vomiting.

Piotr K Janicki

Med Sci Monit 2005; 11(10): RA322-328 :: ID: 430339

Abstract

Postoperative nausea and vomiting (PONV) affects approximately one thirdof patients and may lead to aspiration, dehiscence, esophageal rupture, and increased treatment costsif inadequately controlled. An important therapeutic option for prevention of PONV is 5-hydroxytryptaminetype 3 (5-HT3) receptor antagonists. Nonetheless, therapeutic failure sometimes occurs. Metabolism bythe cytochrome P450 (CYP) system differs among the 5-HT3 receptor antagonists, and provides a rationalexplanation for decreased therapeutic efficacy in some patients. Four of the 5-HT3 receptor antagonistagents (dolasetron, ondansetron, palonosetron, and tropisetron) are metabolized in various degrees viaCYP2D6, an isoform subject to marked genetic polymorphism. In patients with duplicate CYP2D6 alleles,degradation into inactive metabolites occurs rapidly with these four 5-HT3 receptor antagonists, resultingin decreased efficacy for preventing PONV. Granisetron is the only agent in this class that is not metabolizedvia CYP2D6. Instead, granisetron is metabolized via the CYP3A4 isoform, which is not subject to significantgenetic polymorphism. CYP2D6 genotype screening prior to PONV treatment may allow for modification ofantiemetic dosing. An alternative is to use a 5-HT3 agent that is metabolized independently of the CYP2D6isoform, such as granisetron, that would obviate the need for genotyping and may lead to improved prophylaxisof PONV.

Keywords: Genotype, Cytochrome P-450 Enzyme System - metabolism, Cytochrome P-450 CYP2D6 - metabolism, Postoperative Nausea and Vomiting - prevention & control, Serotonin 5-HT3 Receptor Antagonists, Serotonin Antagonists - therapeutic use

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750